RELAY THERAPEUTICS INC (RLAY)
US75943R1023 - Common Stock
RLAY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, RLAY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year RLAY has reported negative net income.
In the past year RLAY has reported a negative cash flow from operations.
RLAY had negative earnings in each of the past 5 years.
In the past 5 years RLAY always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of RLAY (-64.90%) is worse than 63.01% of its industry peers.
With a Return On Equity value of -71.96%, RLAY perfoms like the industry average, outperforming 55.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.9% | ||
| ROE | -71.96% | ||
| ROIC | N/A |
ROA(3y)-34.34%
ROA(5y)-30.19%
ROE(3y)-38.86%
ROE(5y)-33.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RLAY has more shares outstanding
RLAY has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RLAY has an Altman-Z score of 1.03. This is a bad value and indicates that RLAY is not financially healthy and even has some risk of bankruptcy.
RLAY's Altman-Z score of 1.03 is fine compared to the rest of the industry. RLAY outperforms 66.55% of its industry peers.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.03 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
RLAY has a Current Ratio of 18.42. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
RLAY has a better Current ratio (18.42) than 93.98% of its industry peers.
RLAY has a Quick Ratio of 18.42. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
RLAY has a Quick ratio of 18.42. This is amongst the best in the industry. RLAY outperforms 93.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.42 | ||
| Quick Ratio | 18.42 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.97% over the past year.
The Revenue has grown by 37.80% in the past year. This is a very strong growth!
The Revenue for RLAY have been decreasing by -32.39% on average. This is quite bad
EPS 1Y (TTM)2.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)37.8%
Revenue growth 3Y-32.39%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 6.76% on average over the next years.
RLAY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.84% yearly.
EPS Next Y8.27%
EPS Next 2Y1.98%
EPS Next 3Y1.86%
EPS Next 5Y6.76%
Revenue Next Year-39.68%
Revenue Next 2Y-63.06%
Revenue Next 3Y-7.84%
Revenue Next 5Y38.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Also next year RLAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.98%
EPS Next 3Y1.86%
5. Dividend
5.1 Amount
RLAY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RELAY THERAPEUTICS INC
NASDAQ:RLAY (1/14/2025, 8:02:55 PM)
After market: 4.2555 -0.09 (-2.06%)4.345
-0.44 (-9.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.08%
Inst Owner Change0%
Ins Owners1.76%
Ins Owner Change-0.87%
Market Cap727.27M
Analysts86.32
Price Target21.93 (404.72%)
Short Float %9.16%
Short Ratio6.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.61%
Min EPS beat(2)7.69%
Max EPS beat(2)19.53%
EPS beat(4)4
Avg EPS beat(4)12.7%
Min EPS beat(4)7.69%
Max EPS beat(4)19.53%
EPS beat(8)7
Avg EPS beat(8)12.61%
EPS beat(12)8
Avg EPS beat(12)7.42%
EPS beat(16)10
Avg EPS beat(16)3.04%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)3053.38%
Min Revenue beat(4)-100%
Max Revenue beat(4)12513.5%
Revenue beat(8)3
Avg Revenue beat(8)2332.96%
Revenue beat(12)4
Avg Revenue beat(12)1547.02%
Revenue beat(16)6
Avg Revenue beat(16)1189.6%
PT rev (1m)-2.27%
PT rev (3m)-3.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.63%
EPS NY rev (1m)0.69%
EPS NY rev (3m)13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)11.11%
Revenue NY rev (1m)53.95%
Revenue NY rev (3m)52.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 20.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.87 | ||
| P/tB | 0.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.61
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0.21
BVpS5.01
TBVpS5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.9% | ||
| ROE | -71.96% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-34.34%
ROA(5y)-30.19%
ROE(3y)-38.86%
ROE(5y)-33.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.74% | ||
| Cap/Sales | 6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.42 | ||
| Quick Ratio | 18.42 | ||
| Altman-Z | 1.03 |
F-Score4
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)128.66%
Cap/Depr(5y)144.21%
Cap/Sales(3y)262.4%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y8.27%
EPS Next 2Y1.98%
EPS Next 3Y1.86%
EPS Next 5Y6.76%
Revenue 1Y (TTM)37.8%
Revenue growth 3Y-32.39%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-39.68%
Revenue Next 2Y-63.06%
Revenue Next 3Y-7.84%
Revenue Next 5Y38.84%
EBIT growth 1Y-86.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.79%
EBIT Next 3Y-7.78%
EBIT Next 5Y0.18%
FCF growth 1Y-28.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.2%
OCF growth 3YN/A
OCF growth 5YN/A